

Table SI. Status of *Notch1* mutation and TB in nelfinavir-treated *SCL-LMO1* transgenic mice.

No.	Sex	Age, weeks	Weight, g	Tissue	HD exon 26	HD exon 27	JM exon 28	PEST domain exon 34	5' end deletion	TB (%) before	TB (%) end	RR (%)
4830	F	25.0	21.9	Thymus	GL	GL	GL	66392G>AACGG	Negative	100	57.2	42.8
4882	M	16.1	29.6	Thymus	GL	GL	GL	66664CTG>G	Positive	100	34.3	65.7
4655	M	24.7	30.0	Thymus	GL	GL	GL	66391C>CA	Negative	100	31.7	68.3
4661	F	24.7	21.0	Thymus	GL	GL	GL	66505G>GG	Negative	100	26.4	73.6
4829	F	15.9	20.1	Thymus	GL	GL	GL	66280G>CC	Negative	100	21.1	78.9
4767	M	23.9	N/A	Spleen	GL	GL	GL	66279C>CTCCGGGGA	Negative	100	20.4	79.6
4878	M	16.1	27.4	Thymus	GL	GL	GL	66514T>CT	Negative	100	17.4	82.6
4693	F	23.0	22.5	Thymus	GL	GL	GL	GL	Negative	100	13.4	86.6
4716	F	18.4	20.7	BM	GL	GL	GL	66477CC>C	Positive	100	12.6	87.4

Tissue was used for *Notch1* mutation analysis. RR was calculated as follows: TB (%) before - TB (%) end. TB, tumor burden; F, female; M, male; N/A, not available; BM, bone marrow; HD, heterodimerization domain; JM, juxtamembranous domain; GL, germline; PEST, polypeptide enriched in proline, glutamic acid, serine and threonine; RR, response rate.

Table SII. TB in nelfinavir-withdrawal study.

Mouse no.	TB (%) before	TB (%) end	Duration of nelfinavir withdrawal, days	TB (%) relapse <sup>a</sup>
4829	100	21.1	21	140.8
4830	100	57.2	27	104.3
4882	100	34.3	13	48.0
4878	100	17.4	27	67.6

<sup>a</sup>Compared with TB (%) before. TB, tumor burden.